Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

160.63 +0.80 (+0.50%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
48 49 Next >
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Scholar Rock Shares Are Trading Higher Today
Via Benzinga
3 Biotech Stocks to Sell Now
These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead. 
Via InvestorPlace
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors. 
Via Benzinga
Peering Into Biogen's Recent Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of... 
Via Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of... 
Via Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
From Happify Health
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover?
Roche hoped to prevent Alzheimer's disease in patients with a genetic defect. 
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
Via Benzinga
NASDAQ:BIIB Long Term Investor Alert: Investigation of Potential Wrongdoing at Biogen Inc.
San Diego, CA -- (SBWIRE) -- 06/10/2022 -- Certain directors of Biogen Inc. are under investigation over possible breaches of fiduciary duties. 
Via SBWire
Analyzing Biogen's Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has risen 8.63% since its last report. The company recently reported that it has 2.20 million shares sold short, which is 1.51% of... 
Via Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of... 
Via Benzinga
7 No-Brainer Biotech Stocks to Add to Your Buy List
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
Exposures COVID-19
Quant Ratings Updated on 66 Stocks
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10. 
Via InvestorPlace
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
Sage and Biogen say their MDD drug met every goal in a study of postpartum women. 
Via Investor's Business Daily
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.1% on an annualized basis producing an average annual return of 10.04%. Currently, Biogen has a market capitalization of... 
Via Benzinga
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. 
Via InvestorPlace
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 23
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China 
Via Benzinga
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease. 
Via Benzinga
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
Eisai finished submitting its application for lecanemab, another anti-amyloid drug. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.